News for Healthier Living

GEMMABio Announces Clinical Trial Authorization for New SMA1 Gene Therapy

Gemma Biotherapeutics ("GEMMABio"), a leading global genetic medicines company, announced that its novel gene therapy for spinal muscular atrophy type 1 (SMA1) is cleared for clinical trial by ANVISA, the health regulatory agency in Brazil.

November 24, 2025


December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025

November 27 2025

November 26 2025

November 25 2025

November 24 2025

November 23 2025